Denali Therapeutics (DNLI): Assessing Valuation After $200 Million Secondary Offering and FDA Voucher Discussions [Yahoo! Finance]
Denali Therapeutics Inc. (DNLI)
Last denali therapeutics inc. earnings: 8/6 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.denalitherapeutics.com
Company Research
Source: Yahoo! Finance
See our latest analysis for Denali Therapeutics. The $200 million raise comes as Denali's share price sits at $17.47 and tries to rebuild momentum, with a 90 day share price return of 33.87 percent but a 1 year total shareholder return still down 15.93 percent. This underscores how sentiment is improving from a weak longer term base. If this kind of funding and pipeline story has your attention, it is worth also exploring other innovative healthcare stocks that could be next in line for a rerating. With shares still trading well below consensus targets despite rapid revenue growth and fresh funding, investors now face a pivotal question: Is Denali quietly undervalued here, or is the market already pricing in its next leg of growth? On a price-to-book basis, Denali Therapeutics trades at 2.8 times its book value, which leaves it looking slightly expensive versus the broader biotech group. The price-to-book multiple compares what investors pay for each dollar of net assets on
Show less
Read more
Impact Snapshot
Event Time:
DNLI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNLI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNLI alerts
High impacting Denali Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
DNLI
News
- Denali Therapeutics (NASDAQ:DNLI) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $32.00 price target on the stock.MarketBeat
- Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™GlobeNewswire
- How Denali's Brain-Targeted ETV Data and FDA Review Will Impact Denali Therapeutics (DNLI) Investors [Yahoo! Finance]Yahoo! Finance
- Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™ [Yahoo! Finance]Yahoo! Finance
- Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™GlobeNewswire
DNLI
Earnings
- 11/6/25 - Beat
DNLI
Sec Filings
- 2/5/26 - Form 144
- 2/4/26 - Form 144
- 2/3/26 - Form 144
- DNLI's page on the SEC website